Cytarabine

Cytarabine is a type of chemotherapy medicine used to treat certain kinds of leukemia, like acute non-lymphoblastic leukemia. It works by stopping cancer cells from making new DNA. Think of it like blocking the building blocks needed for the cancer cells to grow and multiply.

Brand names:Cytosar, Cytosar-U
Medication

What people taking Cytarabine report

Every report comes from a Lived member, sent anonymously.

Have you tried Cytarabine for AML (Acute Myeloid Leukemia)?

NameHow it went

About Cytarabine

What It's For

Cytarabine, also called ara-C, is a chemotherapy medicine used mainly to treat leukemia, a cancer of the blood-forming cells in the bone marrow. It is approved, in combination with other cancer drugs, to bring acute myeloid leukemia (AML) into remission in adults and children, and it is also used for acute lymphocytic leukemia and for the advanced blast phase of chronic myeloid leukemia. When leukemia reaches the fluid around the brain and spinal cord, or to prevent it from spreading there, cytarabine can be injected directly into that fluid. Doctors sometimes use it for certain non-Hodgkin lymphomas as well. In AML, cytarabine is a backbone of treatment in several ways. Intensive first treatment, called induction, often pairs it with another chemotherapy drug from the anthracycline family such as daunorubicin or idarubicin. After remission, higher-dose cytarabine is commonly used to keep the leukemia from returning. For older adults or people too unwell for intensive chemotherapy, a gentler low-dose version may be combined with venetoclax (Venclexta), a targeted pill. Cytarabine was once sold as Cytosar-U, a brand that has been discontinued in the US; today it is given as generic cytarabine injection. Vyxeos is a separate product that packages cytarabine and daunorubicin together inside tiny fat particles called liposomes. It is approved for specific AML types, including AML that develops after earlier cancer treatment, and has entirely different dosing, so it is never substituted for plain cytarabine.

How It Works

Cancer cells in leukemia divide rapidly, and each division requires copying the cell's DNA. Cytarabine closely resembles deoxycytidine, one of the natural building blocks of DNA. Inside the cell it is converted into an active form that blocks DNA polymerase, the enzyme that assembles new DNA, and it can also be built into DNA itself. Cells caught in the middle of copying their DNA are damaged and die. Because it acts mainly on cells that are actively dividing, cytarabine hits fast-growing leukemia cells hard. It also affects healthy fast-dividing cells, particularly in the bone marrow, the lining of the mouth and gut, and the skin, which explains most of its side effects. The body breaks the drug down quickly, which is why it is given by continuous infusion or repeated doses rather than as a pill, and why it does not work when swallowed.

Dosage & Administration

Cytarabine is always given by a doctor or nurse, under the supervision of a team experienced in cancer chemotherapy. It can be given into a vein as a continuous drip or as shorter infusions, as an injection under the skin, or by injection into the spinal fluid through a lumbar puncture (spinal tap). Doses are calculated from body surface area, an estimate based on height and weight, and vary widely between regimens. In standard AML induction, often called 7 + 3, cytarabine runs as a continuous infusion for seven days while an anthracycline is given on three of those days. This intensive treatment is usually given in the hospital, where blood counts can be checked daily and complications treated quickly. Consolidation with higher-dose cytarabine is typically given in shorter, repeated courses, usually three or four, and low-dose regimens for people who cannot have intensive chemotherapy are repeated in cycles and may continue as long as they are helping. The exact schedule depends on the type of leukemia, the treatment plan and how the blood counts recover between cycles.

Side Effects

The main effect of cytarabine is suppression of the bone marrow, the tissue that makes blood cells. White cells, which fight infection, platelets, which help blood clot, and red cells, which carry oxygen, all fall. Counts often keep dropping for up to about three to four weeks after a course ends before they recover. During this time infections can become serious quickly and bleeding happens more easily. Many people need transfusions and antibiotics, and tiredness is common. Other common effects include nausea, vomiting, loss of appetite, diarrhea, mouth sores, rash, fever, changes in liver tests and irritation of the vein used for the infusion. Some people develop what is called cytarabine syndrome, with fever, muscle and bone aches, rash, red eyes and a general unwell feeling 6 to 12 hours after a dose. Steroid medicines can treat or prevent it. Higher doses carry extra risks. The eyes can become red and painful, so steroid eye drops are usually given to prevent this. Cytarabine can also affect the brain, especially the cerebellum, which controls balance and coordination. Unsteadiness, slurred speech, confusion, unusual sleepiness, personality changes or sudden vision changes should be reported right away, and the drug is stopped or changed if they appear. These effects are usually reversible. Fever is the most important reason to call the oncology team right away, including at night or on weekends. While white cells are low, an infection can become serious very quickly, so a fever, chills, sore throat, ongoing cough or other sign of infection needs an immediate call rather than waiting to see whether it passes. Signs of bleeding from low platelets also need a call right away: unusual bleeding or bruising, black or bloody stools, or vomit that looks like coffee grounds. Call promptly as well for fainting, dizziness or a racing heartbeat, which can reflect low red cells or blood loss, and for yellowing of the skin or eyes, which can signal a liver problem. Call 911 for signs of a severe allergic reaction, such as trouble breathing or swallowing or swelling of the face or throat, and for a seizure.

Interactions & Warnings

Cytarabine can harm a developing baby, with the greatest risk in the first trimester. Pregnancy should be avoided during treatment, and anyone who is pregnant or could become pregnant should discuss this with the care team before starting. Breastfeeding during treatment should also be discussed with the team. People with reduced kidney or liver function are more likely to develop brain and coordination effects from high-dose cytarabine, so doses may be lowered and monitoring increased. When many leukemia cells die at once, they release uric acid and other substances into the blood, so uric acid levels are checked and medicines or fluids may be given to control them. Pancreatitis, a painful inflammation of the pancreas, has been reported, particularly in people previously treated with asparaginase, another leukemia drug. Ongoing stomach pain that spreads to the back can be a sign of it and should be reported right away. Few interactions have been well documented, but some matter during treatment. Levels of digoxin, a heart rhythm medicine, may fall when it is taken with combination chemotherapy, so levels may need checking. Cytarabine may make flucytosine, an antifungal, and gentamicin, an antibiotic, less effective against some infections. Since people with leukemia usually take many medicines, the care team should know about every prescription, over-the-counter medicine and supplement.

What to Expect

Cytarabine is part of a planned course of treatment rather than an ongoing medicine. Intensive induction is usually given in the hospital, and after 7 + 3 it typically takes about four weeks for white cells and platelets to recover. Much of that time is spent watching closely for infection and bleeding while counts are at their lowest. Daily blood tests guide transfusions and antibiotics, and a bone marrow biopsy afterward shows whether the leukemia has gone into remission. Remission is an important step, but treatment generally continues with consolidation courses, often higher-dose cytarabine or a stem cell transplant, to lower the chance of relapse. Each cycle follows a similar pattern: treatment, a drop in counts with tiredness and infection risk, then recovery before the next course. How well the leukemia responds depends heavily on its type and genetic features, and some subtypes, such as core binding factor AML (identified by testing the leukemia cells for specific chromosome changes), respond particularly well to high-dose cytarabine. People receiving low-dose regimens are usually treated as outpatients and continue as long as the treatment is working and tolerated. Most side effects ease once blood counts recover between cycles.

Questions to Ask Your Doctor

  1. 1.What is the goal of cytarabine in my treatment plan, and what other drugs will it be combined with?
  2. 2.Will I be treated in the hospital or as an outpatient, and how long are my blood counts likely to stay low?
  3. 3.Who should I call if I get a fever or bleeding, especially at night or on weekends?
  4. 4.If I receive high-dose cytarabine, how will you check for eye and coordination problems?
  5. 5.How will we know whether the leukemia is responding, and what happens after this phase of treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.